-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Chemotherapy Induced Oral Mucositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Chemotherapy Induced Oral Mucositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Chemotherapy Induced Oral Mucositis Drug Details: Mosedipimod (EC-18)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tirzepatide in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Metastatic Hepatocellular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Nivolumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Cholestasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Cholestasis Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Mosedipimod (EC-18)...
-
Sector Analysis
Clot Management Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Clot Management Devices Market Report Overview The clot management devices market size was $2.13 billion in 2023. The market is expected to grow at a CAGR of more than 3% during 2023-2033. Clot management devices are used for the removal or dissolution of a clot from a blood vessel to restore proper blood circulation. Clot management devices are used as a routine procedure while performing percutaneous coronary intervention and to treat potentially life-threatening complications such as deep vein thrombosis (DVT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Anxiety Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Anxiety Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Anxiety Disorders Drug Details: Brexanolone is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DSP-107 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DSP-107 in Refractory Acute Myeloid Leukemia Drug Details: DSP-107 (KAHR-107) is under development for the...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...